الإحصائيات الأساسية
| LEI | 549300VLGB1D47GGC642 |
| CIK | 1123494 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Harvard Bioscience, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): August 12, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 13, 2025 |
Exhibit 10.1 August 8, 2025 Via Email Mark Frost Re: Retention Benefit Opportunity Dear Mark: We are pleased to inform you that, in recognition of your contributions to Harvard Bioscience, Inc. (the “Company”) and your continued employment through March 15, 2026 (the “Retention Date”) you are being offered the opportunity to receive retention benefits (the “Retention Benefits”) on the fol |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2025 |
Exhibit 10.1 SIXTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT This SIXTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT (this “Amendment”) is entered into as of August 8, 2025, by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), the other Loan Parties party hereto, CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lende |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 11, 2025 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2025 Financial Results · Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations · Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline · New Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., August 11, 2025 (GLOBE NEWSWIRE) |
|
| July 17, 2025 |
Employment Agreement between John Duke and the Company dated July 16, 2025 Exhibit 10.1 HARVARD BIOSCIENCE, INC. EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 16th day of July, 2025 (the “Effective Date”), between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and John Duke (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any of its predecessors. WHEREAS, the Company d |
|
| July 17, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): July 16, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 17, 2025 |
Exhibit 99.1 Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board - Current Board member John Duke to succeed Jim Green as President & CEO - Rob Gagnon and Seth Benson appointed as new Board members - Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, |
|
| June 27, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): June 18, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorpora |
|
| June 23, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): June 18, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 13, 2025 |
UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 Date of Report (Date of earliest event reported): June 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 2, 2025 |
Harvard Bioscience Appoints John Duke to Board of Directors Exhibit 99.1 Harvard Bioscience Appoints John Duke to Board of Directors HOLLISTON, Mass., June 2, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Ead |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 27, 2025 |
Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2024 Forward Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “a |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 12, 2025 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2025 Financial Results HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, “First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 10, 2025 |
Harvard Bioscience Announces CFO Transition Exhibit 99.1 Harvard Bioscience Announces CFO Transition HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective upon the filing of the Company’s Quarterly Report on Form 10-Q, which is expected to be fil |
|
| April 10, 2025 |
Exhibit 10.1 April 10, 2025 Via email Mr. Mark Frost Re: Offer of Employment Dear Mark: On behalf of Harvard Bioscience, Inc. (“HBIO” or the “Company”), I am pleased to extend to you an offer of full-time employment as the Company’s Interim Chief Financial Officer and Treasurer, reporting to me. Your principal place of employment will be the Company’s offices in Holliston, Massachusetts. St |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 14, 2025 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Biochrom Limited United Kingdom CMA Microdialysis Ab Sweden Data Sciences (UK) Mn, Ltd. United Kingdom Data Sciences Eurl France Data Sciences GmbH Germany DSI (Shanghai) Trading Co Ltd. China Harvard Bioscience (Shanghai) Co. Ltd. China Hugo Sachs Elektronik - Harvard Apparatus GmbH Germany Multichannel Systems MCS GmbH Germa |
|
| March 14, 2025 |
EXHIBIT 19 INSIDER TRADING POLICY Revised March 2025 Harvard Bioscience, Inc. and its subsidiaries (collectively, the “Company”) are committed to complying with applicable securities regulations and maintaining the highest ethical standards. We prohibit the trading in Company securities while in possession of material non-public information about the Company. Summary of Key Points ● Trading in Com |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2025 |
HARVARD BIOSCIENCE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical re |
|
| March 12, 2025 |
Exhibit 10.1 FIFTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT This FIFTH AMENDMENT TO AND WAIVER UNDER CREDIT AGREEMENT (this “Amendment”) is entered into as of March 10, 2025, by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), the other Loan Parties party hereto, CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Len |
|
| December 26, 2024 |
HARVARD BIOSCIENCE INC. 84 October Hill Road Holliston, Massachusetts 01746-1371 December 26, 2024 HARVARD BIOSCIENCE INC. 84 October Hill Road Holliston, Massachusetts 01746-1371 December 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Margaret Sawicki Re: Harvard Bioscience Inc. Registration Statement on Form S-3 Filed December 6, 2024 File No. 333-283 |
|
| December 6, 2024 |
As filed with the Securities and Exchange Commission on December 6, 2024 As filed with the Securities and Exchange Commission on December 6, 2024 Registration No. |
|
| December 6, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Harvard Bioscience, Inc. |
|
| November 14, 2024 |
HBIO / Harvard Bioscience, Inc. / 272 Capital LP - HARVARD BIOSCIENCE INC Passive Investment SC 13G/A 1 p24-3162sc13g.htm HARVARD BIOSCIENCE INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 7, 2024 |
Harvard Bioscience Announces Third Quarter 2024 Financial Results Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2024 Financial Results HOLLISTON, Mass., November 7, 2024 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, “Our third quarter revenues continued to reflect the effects of the challenging market environ |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2024 |
Form of Director and Officer Indemnification Agreement Exhibit 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made and entered into this day of 20, by and between Harvard Bioscience, Inc., a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company) and (“Indemnitee”): WHEREAS, it is essential to the Company that |
|
| August 8, 2024 |
Exhibit 10.1 FOURTH AMENDMENT TO CREDIT AGREEMENT This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of August 6, 2024, by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lenders party hereto. W I T N E S S E T H: WHEREAS, the Borrower, the othe |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
Exhibit 10.4 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the “Participant”) have been granted restricted stock units (“Restricted Stock Units” or “RSUs”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the Harvard Bioscience, Inc. 2021 Incentive Plan (as am |
|
| August 8, 2024 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2024 Financial Results HOLLISTON, Mass., August 8, 2024 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, “Second quarter revenues reflect a more challenging than expected market environment. With the unce |
|
| August 8, 2024 |
Exhibit 10.3 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF TIME-BASED RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the “Participant”) have been granted restricted stock units (“Restricted Stock Units” or “RSUs”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended f |
|
| May 29, 2024 |
Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 Forward Looking Statements Forward-looking statements contained in this Conflict Minerals Report (the “Report”) are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which expre |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 14, 2024 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 7, 2024 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2024 Financial Results Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 7, 2024 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As ex |
|
| April 3, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 28, 2024 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 3, 2024 |
Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of March 28, 2024 by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lenders party hereto. W I T N E S S E T H: WHEREAS, the Borrower, the other L |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 21, 2024 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2024 |
Harvard Bioscience Inc., Dodd-Frank Clawback Policy EXHIBIT 97 HARVARD BIOSCIENCE, INC. DODD-FRANK CLAWBACK POLICY This document sets forth the Dodd-Frank Clawback Policy (the “Policy”) as adopted by Harvard Bioscience, Inc. (the “Company”) on October 31, 2023. This Policy shall be interpreted to comply with the clawback rules found in 17 C.F.R. §240.10D and the related listing rules of the national securities exchange or national securities associ |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 7, 2024 |
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2023 Financial Results · Q4 Revenues of $28.2 million · Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) · Q4 operating income of $0.3 million, adjusted operating income of $3.3 million · Strong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage HOLLISTON, Mass., March 7, |
|
| March 7, 2024 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Biochrom Limited United Kingdom Biochrom US, Inc. Delaware, United States CMA Microdialysis Ab Sweden Data Sciences International, Inc. Delaware, United States Data Sciences (UK) Mn, Ltd. United Kingdom Data Sciences Eurl France Data Sciences GmbH Germany DSI (Shanghai) Trading Co Ltd. China Harvard Bioscience (Shanghai) Co. L |
|
| February 14, 2024 |
HBIO / Harvard Bioscience, Inc. / Harvey Partners, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HARVARD BIOSCIENCE, INC. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2024 |
HBIO / Harvard Bioscience, Inc. / PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Harvard Bioscience Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires F |
|
| February 14, 2024 |
HBIO / Harvard Bioscience, Inc. / 272 Capital LP - HARVARD BIOSCIENCE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 13, 2024 |
Harvard Apparatus Regenerative Technology, Inc. / HARVARD BIOSCIENCE INC Passive Investment SC 13G/A 1 sc13ga112799hrgn02142024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Harvard Apparatus Regenerative Technology, Inc. (Name of Issuer) Common Stock, $0.01 par value (Ti |
|
| January 5, 2024 |
Exhibit 99.1 Jim Green, Chairman , President & CEO January 5, 2024 HBIO Investor Overview Enabling discovery, safety and production of tomorrow’s therapeutics Forward - Looking Statements and Non - GAAP Financial Information Forward - Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 7, 2023 |
Harvard Bioscience Announces Third Quarter 2023 Financial Results Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2023 Financial Results · Q3 Revenues of $25.4 million · Q3 Gross Margin of 58.1% · Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million · Continued strong operating cash flow drove debt reduction of $8.3 million through Q3 HOLLISTON, Mass., November 7, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) ( |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2023 |
August 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Disclosure Review Program 100 F Street, N. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 8, 2023 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2023 Financial Results · Q2 Revenues of $28.8 million · Q2 GAAP operating income $0.8 million, adjusted operating income $3.6 million · Strong H1 operating cash flow drove net debt reduction of $5.4 million HOLLISTON, Mass., August 8, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial re |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 20, 2023 |
Employment Agreement between Jennifer Cote and the Company dated June 19, 2023 Exhibit 10.1 HARVARD BIOSCIENCE, INC. EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the date of last signature below (the “Commencement Date”) between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and Jennifer Cote (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any of its predecessors. WHEREAS, t |
|
| June 20, 2023 |
EXHIBIT 99.1 Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice Pre |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 19, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification Number) Incorporation) 84 October Hill Road, Holliston, MA 01746 (Address of Principal E |
|
| May 30, 2023 |
Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 Forward Looking Statements Forward-looking statements contained in this Conflict Minerals Report (the “Report”) are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which expre |
|
| May 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 15, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| April 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 25, 2023 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2023 Financial Results • Q1 Revenues of $30 million up 4% over prior year period • Q1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior year • Q1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “C |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 13, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 6, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 9, 2023 |
Harvard Bioscience Announces Fourth Quarter 2022 Financial Results Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2022 Financial Results HOLLISTON, Mass., March 9, 2023 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative cur |
|
| March 9, 2023 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Asys Hitech GmbH Austria Biochrom Limited United Kingdom Biochrom US, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States CMA Microdialysis Ab Sweden Coulbourn Instruments, LLC Delaware, United States Data Sciences International, Inc. Delaware, United States Data Scienc |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2023 |
Exhibit 10.4 Certain information has been omitted from this document because it is not material and is the type of information the Company treats as private or confidential; such omissions have been marked with the following notation: [OMITTED MATERIAL]. TRADEMARK LICENSE AGREEMENT Effective this 19th day of December 2002, President and Fellows of Harvard College (“Harvard”), a charitable, non-pro |
|
| February 14, 2023 |
HBIO / Harvard Bioscience, Inc. / Harvey Partners, LLC Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HARVARD BIOSCIENCE, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 13, 2023 |
HBIO / Harvard Bioscience, Inc. / PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. Passive Investment SC 13G/A 1 fp0082241-10sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Harvard Bioscience Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 20 |
|
| February 13, 2023 |
HBIO / Harvard Bioscience, Inc. / Portolan Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236395d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d–2. (Amendment No. 2 )* Harvard Bioscience, Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) Decembe |
|
| January 19, 2023 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement (this “Agreement”), dated as of January 18, 2023 (the “Agreement Date”) is entered into by and between Harvard Bioscience, Inc. (the “Company”) and Michael Rossi (“Employee,” and, together with the Company, the “Parties”). All capitalized terms not defined herein shall be given the definition as provided in the employment agre |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 18, 2023 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 3, 2023 |
Letter Agreement between Jennifer Cote and the Company dated December 29, 2022. EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 December 29, 2022 Jennifer Cote Dear Jennifer: I am pleased to offer you the position of Interim Chief Financial Officer and Treasurer of Harvard Bioscience, Inc. (the “Company”), effective as of January 1, 2023, reporting directly to me. In connection with your appointment, we would like to adjust your compensation as follows: 1. Base Salary. Effecti |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 7, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorpor |
|
| January 3, 2023 |
Offer Letter between Jennifer Cote and the Company dated April 28, 2022. EX-10.2 3 exh102.htm EXHIBIT 10.2 Exhibit 10.2 Wednesday, April 27, 2022 Revised: Thursday, April 28, 2022 Jennifer S. Cote Holliston, MA 01746 Sent via Email. Dear Jennifer, Harvard Bioscience “HBIO” is pleased to extend to you a full-time offer of employment as Vice President, Finance based on the terms and subject to the conditions described below. I hope that you will find this new position ch |
|
| December 12, 2022 |
Harvard Bioscience Announces CFO Transition EXHIBIT 99.1 Harvard Bioscience Announces CFO Transition HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced the resignation of Michael Rossi, the Company?s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company?s vice president of global finance, as its interim |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 7, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 9, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of November 8, 2022 by and among HARVARD BIOSCIENCE, INC. (the “Borrower”), CITIZENS BANK, N.A., in its capacity as the Administrative Agent (in such capacity, the “Administrative Agent”), and the Lenders party hereto. W I T N E S S E T H: WHEREAS, the Borrower, the oth |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 8, 2022 |
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2022 Financial Results ?Fighting through challenging times while building the company and new technologies for the future.? HOLLISTON, Mass., November 8, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced financial results for the third quarter ended September 30, 2022. Jim Green, Chairman and CEO, |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 4, 2022 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2022 Financial Results HOLLISTON, Mass., August 3, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced financial results for the second quarter ended June 30, 2022. Jim Green, Chairman and CEO, said, "Our second quarter revenues were essentially flat compared to the prior year quarter as growth in |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| June 21, 2022 |
Harvard Apparatus Regenerative Technology, Inc. / HARVARD BIOSCIENCE INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Biostage, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 09074M202 (CUSIP Number) June 10, 2022 (Date o |
|
| June 8, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Harvard Bioscience, Inc. |
|
| June 8, 2022 |
As filed with the Securities and Exchange Commission on June 8, 2022 As filed with the Securities and Exchange Commission on June 8, 2022 Registration No. |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification Number) Incorporation) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 20, 2022 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 Forward Looking Statements Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation, or inte |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 17, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 17, 2022 |
Harvard Bioscience, Inc. Employee Stock Purchase Plan, as amended Appendix A HARVARD BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN (As Amended) The purpose of the Harvard Bioscience, Inc. Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Harvard Bioscience, Inc. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, par value $.01 per share (the ?Common Stock?). One Million |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 4, 2022 |
Harvard Bioscience Announces First Quarter 2022 Financial Results Exhibit 99.1 Harvard Bioscience Announces First Quarter 2022 Financial Results ? Revenue up 7% year-over-year despite volatility in China related to COVID-19 and global supply chain headwinds HOLLISTON, Mass., May 4, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announced financial results for the first quarter ended March 31, 2022. Jim Green, Chairman and C |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period fromto Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| April 28, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of April 28, 2022 by and among HARVARD BIOSCIENCE, INC. (the ?Borrower?), CITIZENS BANK, N.A. in its capacity as the Administrative Agent (in such capacity, the ?Administrative A |
|
| April 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 27, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| March 11, 2022 |
Form of Performance RSU Award Agreement - 2021 Incentive Plan. Exhibit 10.17 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the ?Participant?) have been granted restricted stock units (?Restricted Stock Units? or ?RSUs?), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the ?Notice?), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended from time t |
|
| March 11, 2022 |
Form of Time-Based RSU Awards Agreement – 2021 Incentive Plan. Exhibit 10.18 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the ?Participant?) have been granted restricted stock units (?Restricted Stock Units? or ?RSUs?), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the ?Notice?), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended from time t |
|
| March 11, 2022 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction AHN Acquisition GmbH Germany Asys Hitech GmbH Austria Biochrom Limited United Kingdom Biochrom US, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States CMA Microdialysis Ab Sweden Coulbourn Instruments, LLC Delaware, United States Data Sciences International, Inc. Delawa |
|
| March 11, 2022 |
Form of RSU Award for Directors – 2021 Incentive Plan. Exhibit 10.19 HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Participant Name and Address: You (the ?Participant?) have been granted restricted stock units (?Restricted Stock Units? or ?RSUs?), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the ?Notice?), the Harvard Bioscience, Inc. 2021 Incentive Plan (as amended from time t |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 8, 2022 |
Harvard Bioscience Announces Fourth Quarter 2021 Financial Results Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2021 Financial Results ? Revenue up 7% year-over-year as sales momentum continues, despite global supply chain headwinds ? Gross margin improves to 59% in Q4 driven by strengthening product mix, improved operating leverage HOLLISTON, Mass., March 8, 2022 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the ?Company?) today announc |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2022 |
HBIO / Harvard Bioscience, Inc. / PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. )* Harvard Bioscience Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fi |
|
| February 11, 2022 |
HBIO / Harvard Bioscience, Inc. / Portolan Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d ?1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d?2. (Amendment No. 1 )* Harvard Bioscience, Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires |
|
| February 8, 2022 |
HBIO / Harvard Bioscience, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Harvard Bioscience Inc (Name of Issuer) Common Stock (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 28, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement (this ?Agreement?), dated as of January 26, 2022 (the ?Agreement Date?) is entered into by and between HARVARD BIOSCIENCE, INC. (the ?Company?) and KEN OLSON (?Employee,? and, together with the Company, the ?Parties?). All capitalized terms not defined herein shall be given the definition as provided in the Parties? September |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 24, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 24, 2022 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period fromto Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 3, 2021 |
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2021 Financial Results Strong double digit revenue growth, solid margin performance despite global supply chain disruptions ? Revenue up 23% year-over-year as sales momentum continues ? Pre-clinical product revenue up 28% ? Cellular and Molecular Technologies (CMT) product revenue up 19% HOLLISTON, Mass., November 3, 2021 (GLOBE NEWSWIRE) - H |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 15, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 3, 2021 |
HBIO / Harvard Bioscience, Inc. / Portolan Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d ?1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d?2. (Amendment No. )* Harvard Bioscience, Inc. (Name of Issuer) Common (Title of Class of Securities) 416906105 (CUSIP Number) August 24, 2021 (Date of Event Which Requires Fili |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 5, 2021 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2021 Financial Results Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 25% year-over-year as sales momentum continues Cellular and Molecular (CMT) product revenue up 22% Pre-clinical product revenue up 20% Operating margins impacted by higher global supply chain costs HOLLISTON, |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2021 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 Forward Looking Statements Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation, or inte |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 19, 2021 |
Harvard Bioscience, Inc. 2021 Incentive Plan. Exhibit 10.1 Harvard Bioscience, Inc. 2021 Incentive Plan Article 1 Establishment and Purpose 1.1 Establishment of the Plan. Harvard Bioscience, Inc., a Delaware corporation (the ?Company?), hereby establishes an incentive compensation plan (as amended from time to time, the ?Plan?), as set forth in this document. 1.2 Purpose of the Plan. The purposes of the Plan are to (a) enable the Company and |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 18, 2021 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 19, 2021 |
As filed with the Securities and Exchange Commission on May 19, 2021 As filed with the Securities and Exchange Commission on May 19, 2021 Registration No. |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 7, 2021 |
EXHIBIT 32.2 CERTIFICATION OF PERIODIC FINANCIAL REPORT PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned officer of Harvard Bioscience, Inc. (the ?Company?) hereby certifies to his knowledge that the Company?s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (the ?Report?) to which this certification is being furnished as an exhibit, as filed with the Securities and Ex |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 6, 2021 |
Exhibit 99.1 Harvard Bioscience Announces First Quarter 2021 Financial Results Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins. ? Revenue up 14% as sales momentum from Q4?20 continues ? Pre-clinical product revenue up 24% ? Operating margin significantly improves year-over-year on GAAP and adjusted basis HOLLISTON, Mass., May |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVAR |
|
| March 17, 2021 |
Subsidiaries Of Harvard Bioscience, Inc. EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Ahn Acquisition Gmbh Germany Asys Hitech Gmbh Austria Biochrom Limited United Kingdom Biochrom Us, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States Cma Microdialysis Ab Sweden Coulbourn Instruments, Llc Delaware, United States Data Sciences International, Inc. Delawa |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 12, 2021 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries Of Harvard Bioscience, Inc. Name Jurisdiction Ahn Acquisition Gmbh Germany Asys Hitech Gmbh Austria Biochrom Limited United Kingdom Biochrom Us, Inc. Delaware, United States Biodrop Ltd. United Kingdom Cartesian Technologies, Inc. Delaware, United States Cma Microdialysis Ab Sweden Coulbourn Instruments, Llc Delaware, United States Data Sciences International, Inc. Delawa |
|
| March 10, 2021 |
Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2020 Financial Results Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt. • Revenue returns to pre-Covid19 levels on strong CRO/pharma sales • Operating margin increased year-over-year on GAAP and an adjusted basis • New debt facility significantly reduces annual interest |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Harvard Bioscience Inc (Name of Issuer) Common Stock (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 23, 2020 |
Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT among HARVARD BIOSCIENCE, INC. EACH OF THE GUARANTORS PARTY HERETO and CITIZENS BANK, N.A., as Administrative Agent Dated as of December 22, 2020 TABLE OF CONTENTS Page Article 1 DEFINITIONS AND RULES OF CONSTRUCTION 1 Section 1.1 Credit Agreement Defined Terms 1 Section 1.2 Uniform Commercial Code Terms and Provisions 1 Section 1.3 Other Defined Terms 1 |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 23, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33957 (Commission File Number |
|
| December 23, 2020 |
Harvard Bioscience Announces New Credit Facility EXHIBIT 99.1 Harvard Bioscience Announces New Credit Facility Improves liquidity and operating flexibility Significantly reduces borrowing costs Supports ongoing transformation to profitable growth platform HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 milli |
|
| December 23, 2020 |
Exhibit 10.1 CREDIT AGREEMENT dated as of December 22, 2020 among HARVARD BIOSCIENCE, INC. as the Borrower, THE LENDERS PARTY HERETO, and CITIZENS BANK, N.A., as Administrative Agent and WELLS FARGO BANK, NATIONAL ASSOCIATION and SILICON VALLEY BANK as Joint Bookrunners, Joint Lead Arrangers and Syndication Agents TABLE OF CONTENTS Page Article 1 Definitions and Rules of Construction 1 Section 1.1 |
|
| December 23, 2020 |
Exhibit 10.3 Execution Version GUARANTEE AGREEMENT among HARVARD BIOSCIENCE, INC. EACH OF THE GUARANTORS PARTY HERETO and CITIZENS BANK, N.A., as Administrative Agent Dated as of December 22, 2020 TABLE OF CONTENTS Page Article 1. DEFINITIONS AND RULES OF CONSTRUCTION 1 Section 1.1 Credit Agreement Defined Terms 1 Section 1.2 Incorporation by Reference 2 Section 1.3 Loan Parties 2 Article 2. GUARA |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 6, 2020 |
Exhibit 4.8 NON-QUALIFIED STOCK OPTION TO PURCHASE SHARES OF COMMON STOCK UNDER THE HARVARD BIOSCIENCE, INC. THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN 111,842 Shares July 18, 2019 (Option Issuance Date) On July 18, 2019, Harvard Bioscience, Inc., a Delaware corporation (including its successors, the “Company”) and Michael Rossi (the “Optionee”) entered into an employment agre |
|
| November 6, 2020 |
Exhibit 4.7 DEFERRED STOCK AWARD AGREEMENT UNDER THE HARVARD BIOSCIENCE, INC. THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED Name of Grantee: Michael Rossi (the “Grantee”) Grant Date: July 18, 2019 (the “Grant Date”) On the Grant Date, Harvard Bioscience, Inc., a Delaware corporation (including its successors, the “Company”) and the Grantee entered into an employment a |
|
| November 6, 2020 |
As filed with the Securities and Exchange Commission on November 6, 2020 Registration No. |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 5, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 5, 2020 |
Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2020 Financial Results Disciplined cost management, cash conservation actions drive increased year-over-year operating income and reduced net debt • Operating margin up year-over-year on GAAP and adjusted basis • Revenue improved sequentially with solid CRO/pharma demand and academic labs reopening • Generated positive operating cash flow in |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| August 10, 2020 |
Harvard Bioscience Inc. Fourth Amended and Restated 2000 Stock Option and Incentive Plan EXHIBIT 10.1 HARVARD BIOSCIENCE, INC. FOURTH AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN 1) GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Harvard Bioscience, Inc. Fourth Amended and Restated 2000 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Independent Directors and other key persons ( |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 5, 2020 |
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2020 Financial Results Accelerated cost reduction, cash conservation actions drive increased operating income, reduced net debt · Operating Income up sequentially and year-over-year on both GAAP and adjusted basis · Cost reduction programs offset expected declines in Academic markets · Net Debt reduced by $2.2 million in Q2 HOLLISTON, Mass., |
|
| June 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) ANDREW FREEDMAN, ESQ. R |
|
| June 15, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 11, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) ANDREW FREEDMAN, ESQ. R |
|
| May 29, 2020 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 Forward Looking Statements Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation, or inte |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of Principal Exe |
|
| May 26, 2020 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| May 8, 2020 |
Form of Director Indemnification Agreement Exhibit 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made and entered into this day of 20, by and between Harvard Bioscience, Inc., a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company) and (“Indemnitee”): WHEREAS, it is essential to the Company that |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 1, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 1, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 5, 2020 |
Harvard Bioscience Announces First Quarter 2020 Financial Results Exhibit 99.1 Harvard Bioscience Announces First Quarter 2020 Financial Results Implemented significant cost reductions to offset Covid-19 impact on operating income HOLLISTON, Mass., May 5, 2020 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months ended March 31, 2020. The Company reported revenue of $23.8 million for the |
|
| May 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 4, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 28, 2020 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 18, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 23, 2020 |
Exhibit 10.1 Paycheck Protection Program Term Note $6,114,700.00 April 18, 2020 FOR VALUE RECEIVED, HARVARD BIOSCIENCE, INC. (the “Borrower”), with an address at 84 OCTOBER HILL ROAD, HOLLISTON, MASSACHUSETTS 01746-1371, promises to pay to the order of PNC BANK, NATIONAL ASSOCIATION (the “Bank”), in lawful money of the United States of America in immediately available funds at its offices located |
|
| April 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 5, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 7, 2020 |
Harvard Bioscience Announces Appointment of Susan Steele to Board of Directors EXHIBIT 99.1 Harvard Bioscience Announces Appointment of Susan Steele to Board of Directors Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders HOLLISTON, Mass., April 06, 2020 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Susan Steele has been appointed to the Company’s Board of Directors as a Class III director, effective |
|
| April 6, 2020 |
HBIO / Harvard Bioscience, Inc. / Engine Capital, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) ANDREW FREEDMAN, ESQ. O |
|
| April 6, 2020 |
begin 644 ex992to13da209488031040620.pdf M)5!$1BTQ+C4-)>+CS],-"C8P(# @;V)J#3P\+TQI;F5AF4@,3 U+U1Y<&4O6%)E9B]76S$@,R Q73X^R!25 )$RH',9'29 !8!FR\@ M"B1S^IC8 +Z]#38CPR,6,C#$SP $& #?EQZ<#0IE;F1S=')E86T-96YD M;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" -"C$P-" P(&]B:@T\ M/"]&:6QT97(O1FQA=&5$96-O9&4O22 R,3,O3" Q.3SE'>SE%0T@5-Z!4 P$ M^@Q\<0Y 6@6(5<%:31@$&/P8TQEG%LP(# @-C$R(#7!E+U!A9V4^/@UE;F1O8FH-C,@,"!O8 |
|
| April 6, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.01 par value, of Harvard Bioscience, Inc., a Delaware corporation. This |
|
| March 16, 2020 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Harvard Bioscience, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), being our common stock, $0.01 par value. The following description of our common stock is a s |
|
| March 16, 2020 |
Form of Market Condition Deferred Stock Award Agreement. EXHIBIT 10.12 DEFERRED STOCK AWARD AGREEMENT UNDER THE HARVARD BIOSCIENCE, INC. THIRD AMENDED AND RESTATED 2000 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED Name of Grantee: (the “Grantee”) Grant Date: (the “Grant Date”) Pursuant to the Harvard Bioscience, Inc. Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the “Plan”), Harvard Bioscience, Inc. (the “Company”) hereby g |
|
| March 16, 2020 |
HBIO / Harvard Bioscience, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 HARVARD BIOSCIENCE, INC. ( |
|
| March 16, 2020 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant AHN Acquisition GmbH (Germany) Asys Hitech GmbH (Austria) Biochrom Limited (United Kingdom) Biochrom US, Inc. (Delaware, United States) BioDrop Ltd. (United Kingdom) Cartesian Technologies, Inc. (Delaware, United States) CMA Microdialysis AB (Sweden) Coulbourn Instruments, LLC (Delaware, United States) Data Sciences International, Inc. (Delaware, United |
|
| March 6, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2020 HARVARD BIOSCIENCE, INC. |
|
| March 6, 2020 |
Exhibit 10.1 Harvard Bioscience March 2, 2020 Chane Graziano 23610 Peppermill Court Bonita Springs, FL 34134 Mr. Graziano: This consulting agreement (this "Agreement") is made by and between Harvard Bioscience, Inc., a Delaware corporation (the "Company"), and Chane Graziano ("you") . 1. Consultation. In consideration of the Company's promises and undertakings in this Agreement, upon request, you |
|
| February 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorpo |
|
| February 26, 2020 |
EXHIBIT 99.1 Harvard Bioscience Announces Fourth Quarter 2019 Financial Results Substantially improves adjusted operating margins while taking actions to underpin 2020 profit and growth targets HOLLISTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three and twelve months ended December 31, 2019. 4th Quar |
|
| February 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2020 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 26, 2020 |
EXHIBIT 99.1 CORRECTION – Harvard Bioscience Announces Fourth Quarter 2019 Financial Results Substantially improves adjusted operating margins while taking actions to underpin 2020 profit and growth targets HOLLISTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) - In a release issued under the same headline issued earlier today by Harvard Bioscience, Inc. (Nasdaq: HBIO), please note that the table titled |
|
| February 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) ANDREW FREEDMAN, ESQ. O |
|
| February 19, 2020 |
ENGINE CAPITAL, L.P. 1345 Avenue of the Americas, 33rd Floor New York, New York 10105 Exhibit 99.2 ENGINE CAPITAL, L.P. 1345 Avenue of the Americas, 33rd Floor New York, New York 10105 February , 2020 Re: Harvard Bioscience, Inc. Dear : Thank you for agreeing to serve as a nominee for election to the Board of Directors of Harvard Bioscience, Inc. (the “Company”) in connection with the proxy solicitation that Engine Capital, L.P. and certain of its affiliates (collectively, the “Eng |
|
| February 19, 2020 |
Exhibit 99.3 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Arnaud Ajdler the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Harvard Bioscience, Inc., a Delaware corporation (the “Company”), direc |
|
| February 19, 2020 |
JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Harvard Bioscience, Inc., a Delaware corporation (the “Company”); WHEREAS, Engine Capital, L.P., Engine Jet Capital, L.P., Engine Capital Management, LP, Engine Capital Management GP, LLC, Engine Investments, LLC and Arnaud Ajdler (together, “Engine”), Melvin L. Keati |
|
| February 12, 2020 |
HBIO / Harvard Bioscience, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HARVARD BIOSCIENCE INC (Name of Issuer) Common Stock (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 7, 2020 |
HBIO / Harvard Bioscience, Inc. / Potomac Capital Management, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| December 23, 2019 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 17, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2019 |
HBIO / Harvard Bioscience, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 5, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 5, 2019 |
EdgarFiling EXHIBIT 10.1 EXECUTION VERSION SECOND AMENDMENT TO FINANCING AGREEMENT SECOND AMENDMENT, dated as of November 5, 2019 (this "Amendment"), to the Financing Agreement, dated as of January 31, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, including any replacement agreement therefor, the "Financing Agreement"), by and among Harvard Biosc |
|
| November 5, 2019 |
Harvard Bioscience Announces Third Quarter Financial Results EXHIBIT 99.1 Harvard Bioscience Announces Third Quarter Financial Results Improves adjusted operating margins while taking actions to underpin next year’s profit and growth targets Q3 Revenue of $27.4 million Q3 Operating Loss (GAAP) of $(1.4) million; Adjusted Operating Income (Non-GAAP) of $3.3 million Q3 GAAP EPS of $(0.07); Adjusted Diluted EPS (Non-GAAP) of $0.04 HOLLISTON, Mass., Nov. 05, 20 |
|
| November 1, 2019 |
Harvard Bioscience Announces Executive Appointment EXHIBIT 99.1 Harvard Bioscience Announces Executive Appointment HOLLISTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green. Singh will lead the newly formed Cellular and Molecular Technologies (CMT) team, whi |
|
| November 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 31, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 1, 2019 |
EdgarFiling EXHIBIT 10.1 HARVARD BIOSCIENCE, INC. EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 31st day of October, 2019, between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and Yash Singh (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any of its predecessors. WHEREAS, the Company desires |
|
| September 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 3, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 4, 2019 |
Harvard Bioscience Elects Alan Edrick to Board of Directors EXHIBIT 99.1 Harvard Bioscience Elects Alan Edrick to Board of Directors HOLLISTON, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that its Board of Directors has elected Alan Edrick to Harvard Bioscience’s Board of Directors, effective September 3, 2019. Bertrand Loy, Lead Independent Director, said “After conducting a thorough search, we are very |
|
| August 8, 2019 |
HBIO / Harvard Bioscience, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. |
|
| July 25, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 25, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 25, 2019 |
Harvard Bioscience Announces Quarter Ended June 30, 2019 Financial Results EXHIBIT 99.1 Harvard Bioscience Announces Quarter Ended June 30, 2019 Financial Results - GAAP and adjusted non-GAAP revenue of $29.6 million - GAAP and adjusted non-GAAP earnings per share of $(0.01) and $0.04, respectively - 2019 guidance remains unchanged HOLLISTON, Mass., July 25, 2019 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), today announced financial results |
|
| July 19, 2019 |
Harvard Bioscience Names Michael Rossi Chief Financial Officer EXHIBIT 99.1 Harvard Bioscience Names Michael Rossi Chief Financial Officer HOLLISTON, Mass., July 18, 2019 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Michael Rossi has been named Chief Financial Officer, effective immediately. Rossi most recently served as Chief Financial Officer of Laborie Medical Technologies, a global medical devices company. Jim Green, Cha |
|
| July 19, 2019 |
EXHIBIT 10.1 HARVARD BIOSCIENCE, INC. EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 18th day of July, 2019, between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and Michael Rossi (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any of its predecessors. WHEREAS, the Company desires to employ Ex |
|
| July 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 18, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 18, 2019 |
Engine Capital LP 1345 Avenue of the Americas, 33rd Floor New York, NY 10105 (212) 321-0048 Exhibit 99.1 Engine Capital LP 1345 Avenue of the Americas, 33rd Floor New York, NY 10105 (212) 321-0048 July 18, 2019 Mr. Jim Green Chairman and CEO Harvard Bioscience, Inc. 84 October Hill Road Holliston, MA 01746 cc: Members of the Board of Directors Dear Jim: Thank you for taking the time to speak with us yesterday. As you know, Engine Capital LP, together with its affiliates (“Engine”), has b |
|
| July 18, 2019 |
HBIO / Harvard Bioscience, Inc. / Engine Capital, L.P. - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) ANDREW FREEDMAN, ESQ. OL |
|
| July 18, 2019 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.01 par value, of Harvard Bioscience, Inc., a Delaware corporation. This |
|
| July 17, 2019 |
HBIO / Harvard Bioscience, Inc. / Potomac Capital Management, Inc. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 416906105 (CUSIP Number) July 9, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| July 17, 2019 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value $0. |
|
| July 8, 2019 |
James Green Named President and CEO of Harvard Bioscience EXHIBIT 99.1 James Green Named President and CEO of Harvard Bioscience HOLLISTON, Mass., July 08, 2019 (GLOBE NEWSWIRE) - Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that James Green has been named President and Chief Executive Officer of the Company by its Board of Directors, effective immediately. Additionally, Harvard Bioscience’s Board has appointed Bertrand Loy as Lead Independent |
|
| July 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 2, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 8, 2019 |
EXHIBIT 10.1 EXECUTION VERSION HARVARD BIOSCIENCE, INC. EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 2nd day of July, 2019, between Harvard Bioscience, Inc., a Delaware corporation (the “Company”), and James Green (“Executive”). For purposes of this Agreement the “Company” shall refer to the Company and any of its predecessors. WHEREAS, the Company desir |
|
| July 8, 2019 |
Separation and Release Agreement between Harvard Bioscience, Inc. and Jeffrey Duchemin. EXHIBIT 10.2 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (the “Release Agreement”) is entered into by Jeffrey Duchemin (the “Executive”) and Harvard Bioscience, Inc. (the “Company”) as of the date that the last party executing this Release Agreement executes the same as noted on the signature page hereto. This is the Release Agreement referenced in the Agreement between |
|
| July 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 416906105 (CUSIP Number) June 28, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| May 30, 2019 |
HBIO / Harvard Bioscience, Inc. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on May 30, 2019 Registration No. |
|
| May 21, 2019 |
Exhibit 1.01 Harvard Bioscience, Inc. Conflict Minerals Report For The Year Ended December 31, 2018 This report for the year ended December 31, 2018 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement reporting and disclosure requirements related to conflict mi |
|
| May 21, 2019 |
HBIO / Harvard Bioscience, Inc. SD - - FORM SD OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Harvard Bioscience, Inc. (Exact name of the registrant as specified in its charter) DELAWARE 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 84 October Hill Road, Holliston, MA 01746 (Address of |
|
| May 20, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 16, 2019 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33957 04-3306140 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2019 |
HBIO / Harvard Bioscience, Inc. / Graziano Chane - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 12) Under the Securities Exchange Act of 1934 HARVARD BIOSCIENCE, INC (Name of Issuer) Common Stock, $0.01 Per Share Par Value (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| May 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2019 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-33957 04-3306140 (State or other jurisdiction of incorporation) (Commission Fi |
